Fredrik Frejd
Chief Scientific Officer & Vice President - Research Affibody AB
Seminars
Thursday 3rd December 2026
Expanding Radiopharmaceuticals Beyond Established Indications Through Engineered Scaffold Proteins
2:00 pm
- Leveraging Affibody molecules to target HER2, HER3, B7-H3 and other emerging oncology targets
- Expanding RLTs into breast, gastric, ovarian, lung and other solid tumours through improved tumour penetration
- Selecting the optimal targeting scaffold for challenging tumour biology
- Translating novel targets into clinically viable radiopharmaceutical programmes
